Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma

Hepato-Gastroenterology

Volumn 51, Issue 58, 2004, Pages 1001-1006

  Nasif, W A ^a   El Emshaty, H M ^b   Tabll, A ^c   Elmasry, S A ^a   Attallah, A M ^d   Gad Elhak, N A ^b  

^a MENOUFIA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

^c NATIONAL RESEARCH CENTRE   (Egypt)

^d Biotechnology Research Center of New Damietta   (Egypt)

Author keywords

DNA ploidy; Immunobiotting; Immunohistochemical; p53; Protein

Indexed keywords

DNA; GENE PRODUCT; MONOCLONAL ANTIBODY; NUCLEAR PROTEIN; P53 MONOCLONAL ANTIBODY; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; ANEUPLOIDY; ARTICLE; CANCER LOCALIZATION; CANCER TISSUE; CLINICAL ARTICLE; COLON; COLON CANCER; COLON MUCOSA; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DIPLOIDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INCIDENCE; LYMPHOCYTIC INFILTRATION; MALE; MONITORING; PLOIDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECTUM; TUMOR; WESTERN BLOTTING;

ADULT; ANEUPLOIDY; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DIPLOIDY; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC TECHNIQUES; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PLOIDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3042567313     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Lee EJ, Gerhold M, Palmer MW, Christen RD: p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection. Br J Cancer 2003; 88:754-759.
2. Monique G, Van Oijen CT, Pieter J: Gain-of-Function mutations in the tumor suppressor gene p53. Clin Can Res 2000; 6:2138-2145.
3. Hinds PW, Weinberg RA: Tumor suppressor genes. Curr Opin Genet Dev 1994; 4:135-141.
4. Prives C, Hall PA: The p53 pathway. J Pathol 1999; 187:122-126.
5. Funk W, Pak DT, Karas RH, Wright WE, Shay JW: A Transcriptionally active DNA-binding sits for human p53 protein complexes. Mol Cell Biol 1992; 12:2866-2871.
6. Fields S, Jang SK: Presence of a potent transcription activating sequence in the p53. Science 1990; 249:1046-1049.
7. May P; May E: Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999; 18:7621-7636.
8. Hollstein M, Sidransky SM, Nau MM, Carbone D, Damico D, Bodner S, et al: p53 gene mutations in non-small-lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogenes 1992; 7:171-178.
9. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, While R, Smits AMM, Bos JL: Genetic mutations during colorectal tumor development. N Engl J Med 1988; 319:525-532.
10. Fearon E, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-767.
11. Morrin M, Kelly M, Barrett N, Delaney P: Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut 1994; 35:1627-1631.
12. Derenzini M, Montanaro L, Chilla A, Tosti E, Ceccarelli C, Dall'Olio F, Ofner D, Trere D: Evaluation of thymidylate synthase protein expression by Western blotting and immunohistochemistry on human colon carcinoma xenografts in nude mice. J Histochem Cytochem 2002; 50:1633-1640.
13. Diamandis EP: Clinical applications of the p53 tumor suppressor gene. Clinical Chimica 1995; 237:79-90.
14. Attallah AM, El-Hak NG, Nasif WA, Tabll A, Ezzat F: Detection of p53 protein overexpression and DNA ploidy analysis in colon cancer. Hepatogastroenterology 1997; 44:1595-1601.
15. Laemimli AS: Cleavage of structural proteins during the assembly of the dead of bacteriophage T40. 1970; 227:680-684.
16. Kropveld A, Rozemuller EH, Leppers FGJ, Scheidel KC, de-Weger RA, Kool R, Slootweg PJ, Tilanus MG: Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of the head and neck squamous cell cancers. Lab Invest 1999; 79:347-353.
17. Harris CC, Hollstein M: Clinical implications of the p53 tumor suppressor gene. New Engl J Med 1993; 329:1318-1327
18. Diez BI, Medrano M, Muguerza JM, Ramos P, Hernandez P, Valletta R, Martin A, Noguerales F, Ruiz A, Granell J: Influence of tumor localization on the prognostic value of P53 protein in colorectal adenocarcinomas. Anticancer Res 2000 20:3907-3912.
19. Goh H-S, Chan C-S, Khine K, Smith DR: p5 and behavior of colorectal cancer. Lancet 1994; 344:233-234.
20. Hamelin R, Laurent-apuig P, Olschwang S, et al: Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994; 106:42-48.
21. Mulder-JWR, Baas IO, Polak MM, Goodman SN, Offerhaus GJA: Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 195; 71:1257-126.
22. Bell SM, Scott N, Cross D, et al: Prognostic value of p53 overexpression and c- ki- ras gene mutations in colorectal cancer. Gastroenterology 1993; 104:57-64.
23. Delattre O, Olschwang S, Law DJ, Meto T, Remvikos Y, Samon RJ. Sastre X, Validire P, Keinberg AP, Thomas G: Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989; 2:353-356.
24. Cripps KJ, Purdie PJ, Carder PJ: A study of stabilization of p53 protein versus point mutation in colorectal carcinoma. Oncogene 1994; 9:2739-2743.
25. Bosari S, Viale G, Bossi P, et al: Cytoplasmic accumulation of p53 protein: An independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 1994; 86:681-687.
26. Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N, Wieand HS: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003; 21:241-250.
27. Starzynska T, Bromley M, Ghosh A, Stern PL: Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. B J Cancer 1992; 66:558-562.
28. Zalata KR, Leech SH, Ming SC, Nasif WA, Nada NA, Mohamed IE, Atallah AM, Gad-el-Hak NA: P53 expression and DNA ploidy pattern in Egyptian colorectal carcinoma. Hepatogastroenterology 2002; 49:1225-1229.
29. Purdie CA, Harrison DJ, Peters A, et al: Tumor incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 1994; 9:603-609.
30. Cianchi F, Balzi M, Beccoiolini A, Giache V, Messerini L, Palomba A, Tisti E, Faraoni P, Chellini F, Pucciani F, Perigli G, Cortesini C: Correlation between DNA content and p53 deletion in colorectal cancer. Eur J Surg 1999; 165:363.
31. Chen HS, Sheen-Chen SM, Lu CC: DNA index and S-phase fraction in curative resection of colorectal adenocarcinoma: analysis of prognosis and current trends. World J Surg 2002; 26:626-630.